On September 11, XTALPI fell 5.14% in regular trading to HKD 6.835, with turnover of HKD 148 million. The decline followed the company's interim report released on September 9, which revealed a significant deterioration in financial performance.

According to the filing, XTALPI reported H1 revenue of RMB 394 million, down 23.9% year-over-year, and swung to a net loss of RMB 225 million from a net profit of RMB 75.6 million in the prior-year period. The revenue decline was primarily driven by a high base effect from a USD 51 million upfront pipeline licensing payment recognized in the same period last year. Drug discovery solutions revenue plunged 54% to RMB 200 million. Adjusted net loss stood at RMB 106 million. R&D expenses surged 66% year-over-year to RMB 368 million, reflecting increased investment in autonomous laboratories and pipeline development. Net cash used in operations widened to RMB 399 million from RMB 238 million a year earlier.

Within the Life Sciences Tools & Services sector, peer INSILICO fell 5.84% on the same day, indicating broad sector pressure. GENSCRIPT BIO rose 1.25%, while WUXI BIO fell 1.31%, WUXI APPTEC fell 1.2%, and WUXI XDC fell 3.01%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)